Committee Chairs:

David Lin, Pfizer Ltd.

Jaime Robledo Cadavid, Bristol-Myers Squibb (Taiwan)

Wei-Li Shao, Eli Lilly and Co.(Taiwan), Inc.

The Pharmaceutical Committee monitors, and whenever possible, influences regulatory development relating to pharmaceutical patents, trademarks and copyright, and disseminates information to the researchbased
pharmaceutical industry. The Committee undertakes projects designed to influence and shape government policy on regulatory matters affecting the pharmaceutical industry and maintains contacts with a wide variety of individuals involved in the health care industry.

製藥委員會

製藥委員會監督並影響與藥品專利、商標、著作權有關的法律修訂，並將相關訊息傳遞給研究導向的製藥業者。委員會透過集體討論，共同影響及形塑與製藥法規有關的政府政策，並且與許多健康照顧業者保持固定聯繫。

Past Committee Meetings/Events:

The Pharmaceutical Committee hosts regular meetings to discuss advocacy and industry issues. Luncheon topics this year include-

New Drug Reimbursement & Pricing
Speaker: Janice Chao-Tzu Chen Chief of Pharmacy Department, Sun Yat-Sen Cancer Center (SYSCC), Taipei / 辜公亮和信治癌中心醫院藥劑科主任 陳昭姿

Healthcare Marketing Solutions for the New Health Reality
Speaker: Joanne Basford, Regional Practice Director, Ogilvy Health, Asia

台灣醫療衛生未來趨勢
Speaker: Dr. Tu Shin-Je, Former Minister of Department of Health (DOH) 涂醒哲先生，前衛生署署長